Immune Response to COVID-19: Can We Benefit from the SARS-CoV and MERS-CoV Pandemic Experience?

Overview

Journal Pathogens

Date 2020 Sep 12

PMID 32916812

Citations 7

Authors

Emilia Sinderewicz

Wioleta Czelejewska

Katarzyna Jezierska-Wozniak

Joanna Staszkiewicz-Chodor

Wojciech Maksymowicz

Affiliations

Soon will be listed here.

Abstract

The global range and high fatality rate of the newest human coronavirus (HCoV) pandemic has made SARS-CoV-2 the focus of the scientific world. Next-generation sequencing of the viral genome and a phylogenetic analysis have shown the high homology of SARS-CoV-2 to other HCoVs that have led to local epidemics in the past. The experience acquired in SARS and MERS epidemics may prove useful in understanding the SARS-CoV-2 pathomechanism and lead to effective treatment and potential vaccine development. This study summarizes the immune response to SARS-CoV, MERS-CoV, and SARS-CoV-2 and focuses on T cell response, humoral immunity, and complement system activation in different stages of HCoVs infections. The study also presents the quantity and frequency of T cell responses, particularly CD4 and CD8; the profile of cytokine production and secretion; and its relation to T cell type, disease severity, and utility in prognostics of the course of SARS, MERS, and COVID-19 outbreaks. The role of interferons in the therapy of these infections is also discussed. Moreover, the kinetics of specific antibody production, the correlation between humoral and cellular immune response and the immunogenicity of the structural HCoVs proteins and their utility in the development of a vaccine against SARS, MERS, and COVID-19 has been updated.

Citing Articles

Immunological and biochemical biomarker alterations among SARS-COV-2 patients with varying disease phenotypes in Uganda.

Drago Kato C, Nsubuga J, Niyonzima N, Kitibwa A, Matovu E, Othieno E BMC Infect Dis. 2023; 23(1):857.

PMID: 38057707 PMC: 10701962. DOI: 10.1186/s12879-023-08854-0.

Reversing the trend: a scoping review of health innovation transfer or exchange from low- and middle-income countries to high-income countries.

Ishimwe M, Kiplagat J, Kadam Knowlton A, Livinski A, Kupfer L BMJ Glob Health. 2023; 8(Suppl 7).

PMID: 37967892 PMC: 10660955. DOI: 10.1136/bmjgh-2023-013583.

Symptomatic MERS-CoV infection reduces the risk of future COVID-19 disease; a retrospective cohort study.

El-Saed A, Othman F, Baffoe-Bonnie H, Almulhem R, Matalqah M, Alshammari L BMC Infect Dis. 2023; 23(1):757.

PMID: 37924004 PMC: 10623690. DOI: 10.1186/s12879-023-08763-2.

Indirect positive health outcomes of COVID-19: a systematic review.

Gebeyehu D, East L, Wark S, Islam M Public Health. 2023; 218:149-159.

PMID: 37040687 PMC: 10015084. DOI: 10.1016/j.puhe.2023.02.005.

SARS-CoV-2 Serum Viral Load and Prognostic Markers Proposal for COVID-19 Pneumonia in Low-Dose Radiation Therapy Treated Patients.

Pique B, Pena K, Riu F, Acosta J, Torres-Royo L, Malave B J Clin Med. 2023; 12(3).

PMID: 36769445 PMC: 9918037. DOI: 10.3390/jcm12030798.

References

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069. PMC: 7042881. DOI: 10.1001/jama.2020.1585. View

Hong K, Choi J, Hong S, Lee J, Kwon J, Kim S . Predictors of mortality in Middle East respiratory syndrome (MERS). Thorax. 2017; 73(3):286-289. DOI: 10.1136/thoraxjnl-2016-209313. View

Hu W, Yen Y, Singh S, Kao C, Wu-Hsieh B . SARS-CoV regulates immune function-related gene expression in human monocytic cells. Viral Immunol. 2012; 25(4):277-88. PMC: 3413073. DOI: 10.1089/vim.2011.0099. View

Castilletti C, Bordi L, Lalle E, Rozera G, Poccia F, Agrati C . Coordinate induction of IFN-alpha and -gamma by SARS-CoV also in the absence of virus replication. Virology. 2005; 341(1):163-9. PMC: 7111739. DOI: 10.1016/j.virol.2005.07.015. View

Guan W, Mok C, Chen Z, Feng L, Li Z, Huang J . Characteristics of Traveler with Middle East Respiratory Syndrome, China, 2015. Emerg Infect Dis. 2015; 21(12):2278-80. PMC: 4672405. DOI: 10.3201/eid2112.151232. View

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H . Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020; 130(5):2620-2629. PMC: 7190990. DOI: 10.1172/JCI137244. View

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Liu X, Shi Y, Li P, Li L, Yi Y, Ma Q . Profile of antibodies to the nucleocapsid protein of the severe acute respiratory syndrome (SARS)-associated coronavirus in probable SARS patients. Clin Diagn Lab Immunol. 2004; 11(1):227-8. PMC: 321358. DOI: 10.1128/cdli.11.1.227-228.2004. View

Bert N, Tan A, Kunasegaran K, Tham C, Hafezi M, Chia A . SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020; 584(7821):457-462. DOI: 10.1038/s41586-020-2550-z. View

10.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

11.

Ksiazek T, Erdman D, Goldsmith C, Zaki S, Peret T, Emery S . A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003; 348(20):1953-66. DOI: 10.1056/NEJMoa030781. View

12.

Jiang Y, Zhao G, Song N, Li P, Chen Y, Guo Y . Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg Microbes Infect. 2018; 7(1):77. PMC: 5915580. DOI: 10.1038/s41426-018-0063-8. View

13.

Strayer D, Dickey R, Carter W . Sensitivity of SARS/MERS CoV to interferons and other drugs based on achievable serum concentrations in humans. Infect Disord Drug Targets. 2014; 14(1):37-43. DOI: 10.2174/1871526514666140713152858. View

14.

Tang F, Quan Y, Xin Z, Wrammert J, Ma M, Lv H . Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study. J Immunol. 2011; 186(12):7264-8. DOI: 10.4049/jimmunol.0903490. View

15.

Li S, Wang C, Jou Y, Huang S, Hsiao L, Wan L . SARS Coronavirus Papain-Like Protease Inhibits the TLR7 Signaling Pathway through Removing Lys63-Linked Polyubiquitination of TRAF3 and TRAF6. Int J Mol Sci. 2016; 17(5). PMC: 4881504. DOI: 10.3390/ijms17050678. View

16.

Barcena M, Oostergetel G, Bartelink W, Faas F, Verkleij A, Rottier P . Cryo-electron tomography of mouse hepatitis virus: Insights into the structure of the coronavirion. Proc Natl Acad Sci U S A. 2009; 106(2):582-7. PMC: 2613939. DOI: 10.1073/pnas.0805270106. View

17.

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y . Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020; 382(13):1199-1207. PMC: 7121484. DOI: 10.1056/NEJMoa2001316. View

18.

Hou H, Wang T, Zhang B, Luo Y, Mao L, Wang F . Detection of IgM and IgG antibodies in patients with coronavirus disease 2019. Clin Transl Immunology. 2020; 9(5):e01136. PMC: 7202656. DOI: 10.1002/cti2.1136. View

19.

Law H, Cheung C, Sia S, Chan Y, Peiris J, Lau Y . Toll-like receptors, chemokine receptors and death receptor ligands responses in SARS coronavirus infected human monocyte derived dendritic cells. BMC Immunol. 2009; 10:35. PMC: 2700820. DOI: 10.1186/1471-2172-10-35. View

20.

Li T, Qiu Z, Han Y, Wang Z, Fan H, Lu W . Rapid loss of both CD4+ and CD8+ T lymphocyte subsets during the acute phase of severe acute respiratory syndrome. Chin Med J (Engl). 2003; 116(7):985-7. View